Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy I-Mab stock | $66.78

Learn how to easily invest in I-Mab stock.

I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 228 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in I-Mab

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

I-Mab stock price (NASDAQ: IMAB)

Use our graph to track the performance of IMAB stocks over time.

I-Mab shares at a glance

Information last updated 2021-10-10.
Latest market close$66.78
52-week range$32.64 - $85.40
50-day moving average $70.74
200-day moving average $68.34
Wall St. target price$94.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.05

Buy I-Mab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy I-Mab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

I-Mab price performance over time

Historical closes compared with the close of $66.78 from 2021-10-14

1 week (2021-10-08) -5.96%
1 month (2021-09-15) -1.97%
3 months (2021-07-15) -9.95%
6 months (2021-04-15) 16.87%
1 year (2020-10-15) 63.48%
2 years (2019-10-11) N/A
3 years (2018-10-11) N/A
5 years (2016-10-11) N/A

Is I-Mab under- or over-valued?

Valuing I-Mab stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of I-Mab's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.


I-Mab's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $168.3 million.

The EBITDA is a measure of a I-Mab's overall financial performance and is widely used to measure a its profitability.

I-Mab financials

Revenue TTM $1.6 billion
Gross profit TTM $1.5 billion
Return on assets TTM -2.86%
Return on equity TTM -0.63%
Profit margin -1.46%
Book value $70.94
Market capitalisation $5.5 billion

TTM: trailing 12 months

Shorting I-Mab shares

There are currently 2.0 million I-Mab shares held short by investors – that's known as I-Mab's "short interest". This figure is 8.6% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting I-Mab shares can be evaluated.

I-Mab's "short interest ratio" (SIR)

I-Mab's "short interest ratio" (SIR) is the quantity of I-Mab shares currently shorted divided by the average quantity of I-Mab shares traded daily (recently around 591459.82142857). I-Mab's SIR currently stands at 3.36. In other words for every 100,000 I-Mab shares traded daily on the market, roughly 3360 shares are currently held short.

However I-Mab's short interest can also be evaluated against the total number of I-Mab shares, or, against the total number of tradable I-Mab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case I-Mab's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 I-Mab shares in existence, roughly 30 shares are currently held short) or 0.0592% of the tradable shares (for every 100,000 tradable I-Mab shares, roughly 59 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against I-Mab.

Find out more about how you can short I-Mab stock.

I-Mab share dividends

We're not expecting I-Mab to pay a dividend over the next 12 months.

I-Mab overview

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. .

Frequently asked questions

What percentage of I-Mab is owned by insiders or institutions?
Currently 0.801% of I-Mab shares are held by insiders and 46.57% by institutions.
How many people work for I-Mab?
Latest data suggests 228 work at I-Mab.
When does the fiscal year end for I-Mab?
I-Mab's fiscal year ends in December.
Where is I-Mab based?
I-Mab's address is: West Tower, OmniVision, Shanghai, China, 201210
What is I-Mab's ISIN number?
I-Mab's international securities identification number is: US44975P1030
What is I-Mab's CUSIP number?
I-Mab's Committee on Uniform Securities Identification Procedures number is: 44975P103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site